

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/075834 A2

(51) International Patent Classification?: A61K

(21) International Application Number: PCT/US03/05046

(22) International Filing Date: 27 February 2003 (27.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/363,364 8 March 2002 (08.03.2002) US

(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GOPALRATH-NAM, Ganopathy [US/US]; 12022 Castlestone Drive, Fishers, IN 46038 (US). HUANG, Lihua [CN/US]; 13138 Penneagle Drive, Carmel, IN 46033 (US). RIGGIN, Ralph, Meridith [US/US]; 708 Suffolk Lane, Carmel, IN 46032 (US). SHELIGA, Theodore, Arsay [US/US]; 7901 Venetian Way, Indianapolis, IN 46217 (US).

(74) Agents: HOSTETTLER, Danica et al.; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GII, GM, IIR, IIU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ACTIVATED PROTEIN C FORMULATIONS

(57) Abstract: The invention relates to pharmaceutical compositions of activated protein C with a chelating agent. Preferably, the formulation contains activated protein C, a chelating agent, a bulking agent, a buffer, and/or a salt with a reconstituted pH between about 5.5 and about 6.5. Alternatively, the chelating agent is added to the diluent used with the activated protein C pharmaceutical composition. The aPC pharmaceutical compositions, formulations, and uses of the invention have improved in-use stability.

WO 03/075834 A2

- 1 -

Title

ACTIVATED PROTEIN C FORMULATIONS

5

Field of the Invention

This invention is in the field of human medicine, particularly in the treatment of vascular disorders with activated protein C. More specifically, the invention relates to pharmaceutical compositions, formulations, and uses of recombinant human activated protein C.

10

Background of the Invention

Protein C is a serine protease and naturally occurring anticoagulant that plays a role in the regulation of homeostasis by inactivating Factors Va and VIIa in the coagulation cascade. Protein C activation results from removal of a dodecapeptide at the 15 N-terminus of the heavy chain, producing activated protein C (aPC) possessing enzymatic activity.

In addition to the enzymatic activities of aPC within the blood coagulation cascade, aPC also can degrade. Activated protein C degradation can lead to variants with anticoagulant activity similar to the full-length chain or to less active variants. According 20 to Foster et al. (WO 91/09951), aPC can include active variants consisting of deletions from the full-length light chain. Foster indicated that such variants include from 149 to 152 amino acid residues and that these light chain deletions do not substantially alter the activity.

In contrast to Foster et al., Applicants discovered that the 1-149 light chain variant 25 was less active while the 1-150, 1-151, and 1-152 variants were active. This less active variant leads to decreased functionality as an anticoagulant via diminished potency.

30

In order to administer aPC to patients, freeze dried formulations of aPC formulation are reconstituted with diluent, added to an intravenous infusion solution, and administered via intravenous transfusion over the course of many hours. This aPC in-use 5 solution has shown decreased potency levels due to the presence of the less active 1-149 aPC C-terminal light chain variant. Therefore, minimizing the level of the 1-149 aPC C-terminal light chain variant degradation product is important in achieving a potent in-use aPC formulation.

Applicants discovered that the addition of a chelating agent to the diluent used 10 with the aPC formulation or to the aPC formulation itself improves the solution stability of aPC. Linnau et al. (AU 9892449) teaches pharmaceutical preparations of at least two blood coagulation factors, including protein C, and involves the use of a chelating agent. Premature thrombin formation in the preparation is prevented if calcium ions are displaced by the presence of magnesium or by the addition of a chelating agent, including 15 EDTA, or related substances, such as citrate. Linnau et al. fail to teach preparations of activated protein C or the effect that metal ions or chelating agents may have on the propensity of activated protein C to form truncated variants or on its stability. Thus, there remains a need in the art to prepare stable, potent formulations of activated protein C. Accordingly, these discoveries allow the preparation of potent in-use aPC formulations to 20 the health care provider that are suitable for administration to a patient in need thereof.

Summary of the Invention

The invention provides a pharmaceutical composition comprising aPC and a chelating agent. The pharmaceutical composition contains the chelating agent.

25 The invention also provides a pharmaceutical composition comprising aPC, a diluent, and a chelating agent. The diluent is either a reconstitution diluent or an intravenous infusion solution wherein the diluent contains the chelating agent.

30 The invention further provides a pharmaceutical composition in the form of a lyophilized formulation. These pharmaceutical compositions contain aPC, a chelating agent, a bulking agent, a buffer, and/or a salt. Upon reconstitution, the pharmaceutical composition has a pH of about 5.5 to 6.5.

- 3 -

The invention also provides a process for preparing a lyophilized formulation of aPC, which comprises freeze drying a pharmaceutical formulation containing activated protein C, a bulking agent, and a chelating agent.

5 Also provided is a process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C with a diluent containing a chelating agent.

Further provided is a process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C and a bulking agent with a diluent containing a chelating agent.

10 Also provided is a method of treating a patient in need thereof which comprises administering to the patient the pharmaceutical composition of the present invention.

Additionally provided is a use of the pharmaceutical composition of the present invention which comprises treating thrombotic disorders.

15

Detailed Description of the Invention

For purposes of the invention, as disclosed and claimed herein, the following terms are as defined below.

20 aPC or activated protein C refers to activated protein C whether recombinant or plasma derived. aPC includes and is preferably human activated protein C although aPC may also include other species or derivatives of activated protein C. Examples of protein C derivatives are selected from the group consisting of Gerlitz, et al., U.S. patent No. 5,453,373, and Foster, et al., U.S. patent No. 5,516,650.

APTT - activated partial thromboplastin time.

25 r-hPC - recombinant human protein C zymogen.

rhAPC - recombinant human activated protein C.

30 r-aPC - recombinant activated protein C produced by activating protein C zymogen in vitro or in vivo or by direct secretion of the activated form of protein C from prokaryotic cells, eukaryotic cells, or transgenic animals including, for example, secretion from human kidney 293 cells as a zymogen then purified and activated by techniques well known to the skilled artisan. Examples are demonstrated in Yan, U.S. Patent No. 4,981,952, and Cottingham, WO 97/20043.

Continuous infusion - continuing substantially uninterrupted the introduction of a solution into a blood vessel for a specified period of time.

Bolus injection - the injection of a drug in a defined quantity (called a bolus) at once.

5 Suitable for administration - a lyophilized formulation or solution that is appropriate to be given as a therapeutic agent.

Zymogen - protein C zymogen, as used herein, refers to secreted, inactive forms, whether one chain or two chains, of protein C.

10 Pharmaceutically acceptable buffer - a pharmaceutically acceptable buffer is known in the art. Pharmaceutically acceptable buffers include sodium phosphate, sodium citrate, sodium acetate, or TRIS.

Chelating agent - a pharmaceutically acceptable multidentate ligand whose molecules can form several bonds to a single metal ion, creating a ring.

15 Diluent - a diluent optionally is a reconstitution diluent or an intravenous infusion solution. A reconstitution diluent is a solution used to restore a lyophilized material to the liquid state. An intravenous infusion solution is a solution used as a vehicle for the administration of pharmaceutical compositions or formulations to a patient. A lyophilized formulation is reconstituted prior to its addition to the intravenous infusion solution.

20 Some examples of diluents, as either reconstitution solutions or intravenous infusion solutions, include 0.9% Sodium Chloride, Sodium Chloride with Potassium Chloride, Glucose and Sodium Chloride, 5% Dextrose, Lactated Ringers, 3% Sodium Chloride, Sterile Water for Injection, and Ringers Injection.

25 EDTA - Ethylenediaminetetraacetic acid that optionally is alone or part of a salt complex. Preferred EDTA forms are selected from the group consisting of dipotassium edetate, disodium edetate, edetate calcium disodium, sodium edetate, trisodium edetate, EDTA free acid, EDTA disodium salt, EDTA disodium salt dihydrate, EDTA disodium-calcium salt, EDTA dipotassium salt, EDTA tripotassium salt EDTA sodium salt, EDTA trisodium salt, EDTA tetrasodium salt hydrate, EDTA tetrasodium salt tetrahydrate, EDTA ferric-sodium salt, EDTA ferric-sodium salt hydrate, and other salts and hydrates.

30 The term edetate is an abbreviation for Ethylenediaminetetraacetic acid.

- 5 -

Activated protein C is an antithrombotic agent with a wider therapeutic index than available anticoagulants, such as heparin and the oral hydroxycoumarin type anticoagulants. Activated protein C is also useful in treating thrombotic disorders. As an antithrombotic agent, aPC has a profound effect on the treatment of a wide variety of 5 acquired disease states involving intravascular coagulation, including thrombotic stroke, deep vein thrombosis, pulmonary embolism, peripheral arterial thrombosis, emboli originating from the heart or peripheral arteries, acute myocardial infarction, disseminated intravascular coagulation, and acute pre or postcapillary occlusions, including transplantations or retina thrombosis. Activated protein C is useful in treating an acquired 10 hypercoagulable state or acquired protein C deficiency associated with sepsis, transplantations, burns, pregnancy, major surgery, trauma, or ARDS. The present formulation provides a method of treating patients by administering a pharmaceutical composition described herein. The present formulation further provides the use of a pharmaceutical composition described herein for treating patients afflicted by one or more 15 of these conditions.

The invention relates to stable formulations and uses of aPC. One stable lyophilized formulation would consist of aPC and a chelating agent. Additionally, a bulking agent is optionally added to the present formulation and selected from the group consisting of mannitol, trehalose, raffinose, and sucrose for use in the lyophilized 20 formulation. Furthermore, the ionic strength is optionally controlled through the salt concentration of the solution. Pharmaceutically acceptable salts typically used to generate ionic strength include but are not limited to potassium chloride (KCl) and sodium chloride (NaCl). The lyophilized product is reconstituted with the appropriate diluent. Preferably, the resulting solution has a pH of about 5.5 to about 6.5. To maintain effective pH 25 control, the aPC solution may contain a pharmaceutically acceptable buffer. Representative buffer systems include Tris-acetate, sodium citrate, and sodium phosphate. A preferable formulation use is a stable lyophilized aPC product that is reconstituted with a diluent containing a chelating agent. Also, a preferable formulation use is a stable lyophilized aPC product that is reconstituted with a diluent then added to an intravenous 30 infusion solution containing a chelating agent or to which a chelating agent will be added.

The molecular interactions in a formulation between aPC, buffer, salt concentration, pH, temperature, and bulking agents, are complex. Yet, the addition of a chelating agent to an aPC formulation with any of the aforementioned components or

parameters or to the diluent used with the aPC formulation inhibits less active 1-149 aPC

5 C-terminal light chain variant degradation products. The formulations of the invention provide stable, enzymatically active, aPC with reduced degradation. The invention has reduced or eliminated any increase in the amount of 1-149 aPC C-terminal light chain variant. Preferably, the levels of 1-149 aPC C-terminal light chain variant do not increase by more than 5%. More preferably, 1-149 aPC C-terminal light chain variant levels do

10 not increase by more than 3%. Even more preferably, the levels of 1-149 aPC C-terminal light chain variant do not increase by more than 2%. Most preferably, the levels of 1-149 aPC C-terminal light chain variant do not increase by more than 1%. This stability is obtained through careful control of the processing and formulation conditions and by the addition of a chelating agent.

15 While the particular source of the aPC is not relevant to the operability of the claimed invention, one illustrative source is depicted in Preparations 1 and 2 below. Preferably the aPC is free of other vitamin-K dependent proteins and factors such as protein S, protein Z, as well as factors II, VII, IX, and X. The formulations described herein are directed to a pharmaceutical product suitable for administration to a patient, either directly, after freeze drying and reconstitution, or, optionally, after dilution in an

20 intravenous infusion solution.

The use of chelating agents for the invention provide a means for sequestering metals that would otherwise promote aPC degradation resulting in the less active 1-149 light chain variant. Representative chelating agents include dipotassium edetate,

25 disodium edetate, edetate calcium disodium, sodium edetate, trisodium edetate, EDTA free acid, EDTA disodium salt, EDTA disodium salt dihydrate, EDTA disodium-calcium salt, EDTA dipotassium salt, EDTA tripotassium salt EDTA sodium salt, EDTA trisodium salt, EDTA tetrasodium salt hydrate, EDTA tetrasodium salt tetrahydrate, EDTA ferric-sodium salt, EDTA ferric-sodium salt hydrate, and other salts and hydrates.

30 The most preferred chelating agent is EDTA disodium salt. The skilled artisan will recognize that many other chelating agents are available for use in the formulations of the

invention. The optimum concentration of chelating agent is dependent on the amount of metals present in the diluent. Yet, as long as a sufficient concentration of chelating agent is used to sequester all available metals, any excess of chelating agent beyond the necessary amount will have no undue effect on the pharmaceutical composition or

5 formulation. However, the skilled artisan will recognize that the upper range for the amount of chelating agent used is within physiological tolerance. Primarily, the amount of chelating agent is determined based on the aPC concentration. Preferably, the amount of chelating agent is from 1 μ M to 10 mM. More preferably, the amount of chelating agent is from 20 μ M to 5 mM. The preferred concentration of chelating agent when using 10 2.5 mg/mL aPC is 1 μ M to 10 mM. A more preferred concentration of chelating agent when using 2.5 mg/mL aPC is 20 μ M to 5 mM. Even more preferably, the concentration of chelating agent when using 2.5 mg/mL aPC is 50 μ M to 1 mM. The most preferred concentration of chelating agent when using 2.5 mg/mL aPC is 500 μ M. Alternatively, the preferred concentration of chelating agent when using 5 mg/mL aPC is 1 μ M to 10 15 mM. A more preferred concentration of chelating agent when using 5 mg/mL aPC is 20 μ M to 5 mM. Even more preferably, the concentration of chelating agent when using 5 mg/mL aPC is 500 μ M to 3 mM. The most preferred concentration of chelating agent when using 5 mg/mL aPC is 1 mM. Using a chelating agent with the diluent containing the formulation stabilizes the aPC for at least 24 hours at room temperature.

20 Preferred bulking agents in the formulation of aPC are sucrose, trehalose and raffinose. More preferred bulking agents are sucrose and raffinose. The most preferred bulking agent is sucrose. The amount of bulking agent in the formulation is 1 part aPC to 1 to 10 parts bulking agent on a weight-to-weight basis. Moreover, the bulking agent concentration of the formulation is an important formulation variable of the freeze drying process. The optimum concentration of bulking agent is dependent on the amount of aPC 25 and species of bulking agent selected. The preferred concentration of sucrose in the freezing solution is 10 to 40 mg/mL. A more preferred concentration of sucrose is 15 to 30 mg/mL. The most preferred concentration of sucrose in the freezing solution is 15 mg/mL in a formulation of aPC at 2.5 mg/mL. The most preferred concentration of sucrose in the freezing solution is 30 mg/mL in a formulation of aPC at 5.0 mg/mL. The

presence of the bulking agent in the formulation of aPC offers increased chemical and physical stability.

5 Prior to freeze drying and upon reconstitution, it is preferable to maintain the pH in the range of 5.5 to 6.5 to minimize solution state autodegradation. The preferred pH of the formulation is a pH between about pH 5.6 and about pH 6.4. More preferred is a pH between about 5.7 to about 6.3. Even more preferred is a pH between about 5.8 to about 6.2. Still even more preferred is a pH between about 5.9 to about 6.1. The most preferred pH is about pH 6.0.

10 To maintain effective pH control, the aPC solution may contain a pharmaceutically acceptable buffer. Accordingly, upon freeze-drying, the formulation optionally and preferably comprises a pharmaceutically acceptable buffer. Representative buffer systems include Tris-acetate, sodium citrate, and sodium phosphate. More preferred buffer systems include sodium citrate and sodium phosphate. The most preferred buffer is sodium citrate. The preferred molarity of the buffer system is 10 mM to 50 mM. A more preferred molarity of the buffer system is 10 mM to 20 mM. The most preferred molarity is 40 mM. The skilled artisan will recognize that many other buffer systems are available for use in the formulations of the invention.

15 Similarly, during freeze drying and upon reconstitution, the ionic strength is controlled to ensure solution state stability. The ionic strength is generally determined by the salt concentration of the solution. Pharmaceutically acceptable salts typically used to generate ionic strength include but are not limited to potassium chloride (KCl) and sodium chloride (NaCl). The preferred salt in the invention is sodium chloride. Preferably, the sodium chloride concentration is greater than 150 mM. More preferably, the sodium chloride concentration in the freezing solution is between 150 mM to 1000 mM. For a formulation containing 2.5 mg/mL aPC, the more preferable sodium chloride concentration in the freezing solution is between 150 mM to 650 mM. Even more preferably the sodium chloride concentration in the freezing solution is between 250 mM to 450 mM. Still even more preferably the sodium chloride concentration in the freezing solution is between 300 mM to 400 mM. The most preferable sodium chloride concentration in the freezing solution is 325 mM for a formulation containing 2.5 mg/mL aPC.

Similarly, for a formulation containing 5.0 mg/mL aPC, the more preferable sodium chloride concentration in the freezing solution is between 150 mM to 1000 mM. Even more preferably the sodium chloride concentration in the freezing solution is between 250 mM to 750 mM. Still even more preferably the sodium chloride concentration in the freezing solution is between 400 mM to 700 mM. The most preferable sodium chloride concentration in the freezing solution is 650 mM for a formulation containing 5.0 mg/mL aPC.

The ratio of aPC:salt:bulking agent (w:w:w) is an important factor in a formulation suitable for the freeze drying process. The ratio varies depending on the concentration of aPC, salt selection and concentration and bulking agent selection and concentration. Particularly, a weight ratio of one part aPC to between about 7 to 8 parts salt to between about 5 to 7 parts bulking agent is preferred. More preferred is a weight ratio of one part aPC to between about 7.5 to about 8 parts salt to between about 5.5 to about 6.5 parts bulking agent. Most preferred is a ratio of about 1 part aPC to about 7.6 parts salt to about 6 parts bulking agent.

The preferred salt is sodium chloride at a concentration of 325 mM (for a formulation containing 2.5 mg/mL aPC) and 650 mM (for a formulation containing 5.0 mg/mL aPC) and at a ratio of about 1.3:1 with sucrose (w:w). This concentration is high enough to cause the salt to crystallize during the freezing process, most likely resulting in an amorphous mixture of aPC, sucrose, and citrate that can be lyophilized. Thus, the ionic strength of NaCl at the preferred concentrations of 325 mM and 650 mM convey stability to the formulation during the freeze-drying process.

The invention also provides a process for preparing a stable lyophilized formulation which comprises lyophilizing a solution comprising aPC and a chelating agent, preferably about 2.5 mg/mL aPC, about 15 mg/mL sucrose, about 19 mg/mL NaCl, about 500 μ M EDTA Disodium, and a sodium citrate buffer having a pH greater than 5.5 but less than 6.5. Furthermore, the invention provides a process for preparing a stable lyophilized formulation which comprises lyophilizing a solution comprising about 5 mg/mL aPC, about 30 mg/mL sucrose, about 38 mg/mL NaCl, about 1 mM EDTA Disodium, and a citrate buffer having a pH greater than 5.5 but less than 6.5. Such a lyophilization is conducted by routine methods in the art.

- 10 -

Additionally, the invention provides a method of treating disease states involving intravascular coagulation comprising administration of the formulation.

The aPC is preferably administered parenterally to ensure its delivery into the bloodstream in an effective form by injecting the appropriate dose as continuous infusion

5 for about one to about ninety-six hours. The amount of aPC administered is from about 0.01 mg/kg/hr to about 0.05 mg/kg/hr. Alternatively, the aPC will be administered by injecting a portion of the appropriate dose per hour as a bolus injection over a time from about 5 minutes to about 30 minutes, followed by continuous infusion of the appropriate dose for about twenty-three hours to about 47 hours, resulting in the appropriate dose

10 administered over 24 hours to 48 hours.

The following examples will help describe how the invention is practiced and will illustrate the invention. The scope of the invention is not to be construed as merely consisting of the following examples.

15

Preparation 1

Preparation of Human Protein C

Recombinant human protein C (r-hPC) was produced in Human Kidney 293 cells by techniques well known to the skilled artisan such as those set forth in Yan, U.S. Patent No. 4,981,952, the entire teaching of which is herein incorporated by reference. The gene encoding human protein C is disclosed and claimed in Bang, et al., U.S. Patent No. 4,775,624, the entire teaching of which is incorporated herein by reference. The plasmid used to express human protein C in 293 cells was plasmid pLPC which is disclosed in Bang, et al., U.S. Patent No. 4,992,373, the entire teaching of which is incorporated herein by reference. The construction of plasmid pLPC is also described in European Patent

20 Publication No. 0 445 939, and in Grinnell, et al., 1987, Bio/Technology 5:1189-1192, the teachings of which are also incorporated herein by reference. Briefly, the plasmid was transfected into 293 cells, then stable transformants were identified, subcultured and grown in serum-free media. After fermentation, cell-free medium was obtained by microfiltration.

25

30 The human protein C was separated from the culture fluid by an adaptation of the techniques of Yan, U.S. Patent No. 4,981,952. The clarified medium was made 4 mM in

- 11 -

EDTA Disodium before it was absorbed to an anion exchange resin (Fast-Flow Q, Pharmacia). After washing with 4 column volumes of 20 mM Tris, 200 mM NaCl, pH 7.4 and 2 column volumes of 20 mM Tris, 150 mM NaCl, pH 7.4, the bound recombinant human protein C zymogen was eluted with 20 mM Tris, 150 mM NaCl, 10 mM CaCl₂, pH 7.4. The eluted protein was greater than 95% pure after elution as judged by SDS-polyacrylamide gel electrophoresis.

5 Further purification of the protein was accomplished by making the protein 3 M in NaCl followed by adsorption to a hydrophobic interaction resin (Toyopearl Phenyl 650 M, TosoHaas) equilibrated in 20 mM Tris, 3 M NaCl, 10 mM CaCl₂, pH 7.4. After washing 10 with 2 column volumes of equilibration buffer without CaCl₂, the recombinant human protein C was eluted with 20 mM Tris, pH 7.4.

10 The eluted protein was prepared for activation by removal of residual calcium. The recombinant human protein C was passed over a metal affinity column (Chelex-100, Bio-Rad) to remove calcium and again bound to an anion exchanger (Fast Flow Q, 15 Pharmacia). Both of these columns were arranged in series and equilibrated in 20 mM Tris, 150 mM NaCl, 5 mM EDTA Disodium, pH 7.4. Following loading of the protein, the Chelex-100 column was washed with one column volume of the same buffer before disconnecting it from the series. The anion exchange column was washed with 3 column 20 volumes of equilibration buffer before eluting the protein with 0.4 M NaCl, 20 mM Tris-acetate, pH 6.5. Protein concentrations of recombinant human protein C and recombinant aPC solutions were measured by UV 280 nm extinction E0.1% = 1.81 or 1.85, respectively.

Preparation 2

Activation of Recombinant Human Protein C

25 Bovine thrombin was coupled to Activated CH-Sepharose 4B (Pharmacia) in the presence of 50 mM HEPES, pH 7.5 at 4°C. The coupling reaction was done on resin already packed into a column using approximately 5000 units thrombin/mL resin. The thrombin solution was circulated through the column for approximately 3 hours before adding 2-amino-ethanol (MEA) to a concentration of 0.6 mL/L of circulating solution. 30 The MEA-containing solution was circulated for an additional 10-12 hours to assure complete blockage of the unreacted amines on the resin. Following blocking, the

- 12 -

thrombin-coupled resin was washed with 10 column volumes of 1 M NaCl, 20 mM Tris, pH 6.5 to remove all non-specifically bound protein, and was used in activation reactions after equilibrating in activation buffer.

5 Purified r-hPC was made 5 mM in EDTA Disodium (to chelate any residual calcium) and diluted to a concentration of 2 mg/mL with 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5. This material was passed through a thrombin column equilibrated at 37°C with 50 mM NaCl and either 20 mM Tris pH 7.4 or 20 mM Tris-acetate pH 6.5. The flow rate was adjusted to allow for approximately 20 min. of contact time between the r-hPC and thrombin resin. The effluent was collected and immediately assayed for

10 amidolytic activity. If the material did not have a specific activity (amidolytic) comparable to an established standard of aPC, it was recycled over the thrombin column to activate the r-hPC to completion. This was followed by 1:1 dilution of the material with 20 mM buffer as above, with a pH of either 7.4 or 6.5 to keep the aPC at lower concentrations while it awaited the next processing step.

15 Removal of leached thrombin from the aPC material was accomplished by binding the aPC to an anion exchange resin (Fast Flow Q, Pharmacia) equilibrated in activation buffer (either 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5) with 150 mM NaCl. Thrombin does not interact with the anion exchange resin under these conditions, but passes through the column into the sample application effluent. Once the aPC is loaded

20 onto the column, a 2-6 column volume wash with 20 mM equilibration buffer is done before eluting the bound aPC with a step elution using 0.4 M NaCl in either 5 mM Tris-acetate, pH 6.5 or 20 mM Tris, pH 7.4. Higher volume washes of the column facilitated more complete removal of the dodecapeptide. The material eluted from this column was stored either in a frozen solution (-20°C) or as a lyophilized powder.

25 The anticoagulant activity of aPC was determined by measuring the prolongation of the clotting time in the activated partial thromboplastin time (APTT) clotting assay. A standard curve was prepared in dilution buffer (1 mg/mL radioimmunoassay grade bovine serum albumin [BSA], 20 mM Tris, pH 7.4, 150 mM NaCl, 0.02% NaN3) ranging in protein C concentration from 125-1000 ng/mL, while samples were prepared at several

30 dilutions in this concentration range. To each sample cuvette, 50 µL of cold horse plasma and 50 µL of reconstituted activated partial thromboplastin time reagent (APTT Reagent,

- 13 -

Sigma) were added and incubated at 37°C for 5 min. After incubation, 50 µL of the appropriate samples or standards were added to each cuvette. Dilution buffer was used in place of sample or standard to determine basal clotting time. The timer of the fibrometer (CoA Screener Hemostasis Analyzer, American Labor) was started immediately after the addition of 50 µL 37°C 30 mM CaCl₂ to each sample or standard. Activated protein C concentration in samples is calculated from the linear regression equation of the standard curve. Clotting times reported here are the average of a minimum of three replicates, including standard curve samples.

10

Example 1

Intravenous infusion solution stability studies in the vial (~1-mg/mL) with freshly prepared and filtered 0.9% sodium chloride solution (made at Eli Lilly and Company) containing 5mM, 10mM, and 20mM EDTA Disodium were conducted using a rhAPC formulation (made at Eli Lilly and Company; 2 mg/mL aPC, 15.2 mg/mL sucrose, 12 mg/mL NaCl, and a citrate buffer having a pH greater than 5.5 but less than 6.5). The 1-mg/mL I.V. Solutions of rhAPC Formulation prepared in 0.9% sodium chloride solution (made at Eli Lilly and Company), sterile Water for Injection, USP, and in a 150-mL Abbott PVC I.V. bag of 0.9% Sodium Chloride Injection, USP served as controls. The C-Terminal Light Chain Variant (by LC/MS) results from these studies are presented in Tables 1A and 1B.

- 14 -

Table 1A: C-Terminal Light Chain Variant Results for ~1-mg/mL I.V. Solution of rhAPC Formulation in the Vial with Freshly Prepared 0.9% Sodium Chloride Solution and sterile Water for Injection, USP (Control), and in 0.9% Sodium Chloride Solution Containing 5mM, 10mM, and 20mM EDTA Disodium

| Sample Description | C-Terminal Light Chain Variant (%) |
|---|------------------------------------|
| Initial 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution (Control) | 1-149: ND |
| 24-Hour 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution (Control) | 1-149: 59% |
| 24-Hour 1-mg/mL I.V. Solution with Sterile Water for Injection (Control) | 1-149: 19% |
| Initial 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution Containing 5mM EDTA Disodium | 1-149: ND |
| 24-Hour 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution Containing 5mM EDTA Disodium | 1-149: ND |
| Initial 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution Containing 10mM EDTA Disodium | 1-149: ND |
| 24-Hour 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution Containing 10mM EDTA Disodium | 1-149: ND |
| Initial 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution Containing 20mM EDTA Disodium | 1-149: ND |
| 24-Hour 1-mg/mL I.V. Solution with Freshly Prepared 0.9% Sodium Chloride Solution Containing 20mM EDTA Disodium | 1-149: ND |

N/A = Not Applicable; ND = Detection Limit is <2%

- 15 -

Table 1B: C-Terminal Light Chain Variant Results for ~1-mg/mL I.V. Solution of rhAPC Formulation in Sterile Polypropylene Tubes and in a 150-mL Abbott PVC I.V. Bag of 0.9% Sodium Chloride Injection, USP (Control), and in 0.9% Sodium Chloride Solution Containing 5mM, 1mM, 0.2mM, 0.04mM EDTA Disodium

| Sample Description | C-Terminal Light Chain Variant (%) |
|---|------------------------------------|
| Initial 1-mg/mL I.V. Solution in a 150-mL PVC I.V. Bag of 0.9% Sodium Chloride Solution (Control) | 1-149: 6% |
| 24-Hour 1-mg/mL I.V. Solution in a 150-mL PVC I.V. Bag of 0.9% Sodium Chloride Solution (Control) | 1-149: 78% |
| 24-Hour 1-mg/mL I.V. Solution in a 150-mL PVC I.V. Bag of 0.9% Sodium Chloride Solution Containing 5mM EDTA Disodium | 1-149: ND |
| 24-Hour 1-mg/mL I.V. Solution in a 150-mL PVC I.V. Bag of 0.9% Sodium Chloride Solution Containing 1mM EDTA Disodium | 1-149: ND |
| 24-Hour 1-mg/mL I.V. Solution in a 150-mL PVC I.V. Bag of 0.9% Sodium Chloride Solution Containing 0.2mM EDTA Disodium | 1-149: ND |
| 24-Hour 1-mg/mL I.V. Solution in a 150-mL PVC I.V. Bag of 0.9% Sodium Chloride Solution Containing 0.04mM EDTA Disodium | 1-149: ND |

5

N/A = Not Applicable; ND = Non-detected.
Detection Limit is <2%

Example 2

Intravenous infusion solution stability studies of a 200- μ g/mL rhAPC I.V. 10 solutions in a 150-mL B. Braun/McGaw PAB® I.V. Bag of 0.9% Sodium Chloride Injection, USP (Control) and in 150-mL B. Braun/McGaw PAB® I.V. Bags of 0.9% Sodium Chloride Injection, USP containing 20 μ M, 50 μ M, and 100 μ M, respectively, of EDTA Disodium were conducted using a rhAPC formulation (made at Eli Lilly and Company; 2 mg/mL aPC, 15.2 mg/mL sucrose, 12 mg/mL NaCl, and a citrate buffer 15 having a pH greater than 5.5 but less than 6.5). The rhAPC concentration, potency, and

- 16 -

pH results from these studies are presented in Table 2A. The LC/MS results from these studies are presented in Table 2B.

5 Table 2A: rhAPC Concentration, Potency and pH Results for ~200- μ g/mL I.V. Solutions of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% Sodium Chloride Injection, USP (Control), and in 150-mL PAB® I.V. Bags of 0.9% Sodium Chloride Injection, USP Containing 20 μ M, 50 μ M, and 100 μ M EDTA Disodium

| Sample Description | rhAPC Conc. | Potency | pH |
|--|----------------|-----------|------|
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. (Control) | 210 μ g/mL | 456 U/mg | 5.98 |
| 8-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. (Control) | 210 μ g/mL | 338 U/mg | ND |
| 12-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. (Control) | 210 μ g/mL | 315 U/mg | ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. (Control) | 210 μ g/mL | 249 U/mg | 6.03 |
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 20 μ M EDTA Disodium | 190 μ g/mL | 464 U/mg* | 6.00 |
| 8-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 20 μ M EDTA Disodium | 190 μ g/mL | 450 U/mg* | ND |
| 12-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 20 μ M EDTA Disodium | 190 μ g/mL | 434 U/mg* | ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 20 μ M EDTA Disodium | 190 μ g/mL | 422 U/mg* | 6.01 |

N/A = Not Applicable ND = Not Determined

* The average of three analyses is reported

- 17 -

Table 2A continued:

| Sample Description | rhAPC Conc. | Potency | pH |
|---|----------------|----------|------|
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 50 μ M EDTA Disodium | 210 μ g/mL | 479 U/mg | 5.99 |
| 8-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 50 μ M EDTA Disodium | N/A | 461 U/mg | ND |
| 12-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 50 μ M EDTA Disodium | N/A | 465 U/mg | ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 50 μ M EDTA Disodium | 220 μ g/mL | 428 U/mg | 6.00 |
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 100 μ M EDTA Disodium | 210 μ g/mL | 498 U/mg | 5.98 |
| 8-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 100 μ M EDTA Disodium | N/A | 475 U/mg | ND |
| 12-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 100 μ M EDTA Disodium | N/A | 470 U/mg | ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 100 μ M EDTA Disodium | 220 μ g/mL | 451 U/mg | 6.00 |

N/A = Not Applicable ND = Not Determined

- 18 -

Table 2B: C-Terminal Light Chain Variant Results for ~200- μ g/mL I.V. Solutions of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% Sodium Chloride Injection, USP (Control), and in 150-mL PAB® I.V. Bags of 0.9% Sodium Chloride Injection, USP Containing 20 μ M, 50 μ M, and 100 μ M EDTA Disodium

5

| Sample Description | C-Terminal Light Chain Variant (%) |
|---|------------------------------------|
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. (Control) | 1-149: ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. (Control) | 1-149: 79% |
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 20 μ M EDTA Disodium | 1-149: ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 20 μ M EDTA Disodium | 1-149: ND |
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 50 μ M EDTA Disodium | 1-149: ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 50 μ M EDTA Disodium | 1-149: ND |
| Initial 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 100 μ M EDTA Disodium | 1-149: ND |
| 24-Hour 200- μ g/mL I.V. Solution of rhAPC Formulation in a 150-mL PAB® I.V. Bag of 0.9% NaCl Inj. Containing 100 μ M EDTA Disodium | 1-149: ND |

N/A = Not Applicable; ND = Non-detected.
Detection Limit is <2%

Example 3

A stable lyophilized formulation is made by lyophilizing a solution comprising 2.5 mg/mL aPC, 15 mg/mL sucrose, 19 mg/mL NaCl, 500 μ M EDTA Disodium, and a sodium citrate buffer having a pH greater than 5.5 but less than 6.5. Also, a stable lyophilized formulation is made by lyophilizing a solution comprising 5 mg/mL aPC, 30 mg/mL sucrose, 38 mg/mL NaCl, 1 mM EDTA Disodium, and a citrate buffer having a pH greater than 5.5 but less than 6.5.

10

Example 4

A stable lyophilized formulation is made by lyophilizing a solution comprising 2.5 mg/mL aPC, 15 mg/mL sucrose, 19 mg/mL NaCl, and a sodium citrate buffer having a pH greater than 5.5 but less than 6.5. Also, a stable lyophilized formulation is made by lyophilizing a solution comprising 5 mg/mL aPC, 30 mg/mL sucrose, 38 mg/mL NaCl, and a citrate buffer having a pH greater than 5.5 but less than 6.5. Prior to freeze drying and upon reconstitution, the pH is maintained in the range of 5.5 to 6.5. When the lyophilized formulation is reconstituted, the reconstitution diluent contains a sufficient amount of EDTA Disodium to provide 100 μ M in the reconstituted solution. Alternatively, the reconstituted formulation is added to a diluent suitable for administration to a patient, such as an intravenous infusion solution, containing a sufficient amount of EDTA Disodium to provide 100 μ M in the infusion solution.

- 20 -

We claim:

1. A pharmaceutical composition comprising activated protein C and a chelating agent.

5

2. The composition of claim 1 wherein the pharmaceutical composition is a lyophilized formulation.

3. The composition of claim 2 further comprising a bulking agent.

10

4. The composition of claim 3 wherein the bulking agent is selected from mannitol, trehalose, raffinose, and sucrose, and mixtures thereof.

5. The composition of claim 4 further comprising a buffer selected from Tris-acetate, 15 sodium citrate and sodium phosphate, or combinations thereof.

6. The composition of claim 5 further comprising a buffer such that upon reconstitution the formulation has a pH of about 5.5 to about 6.5.

20 7. The composition of claim 6 further comprising a salt.

8. The composition of claim 7 wherein the salt is selected from potassium chloride or sodium chloride.

25 9. A pharmaceutical composition comprising activated protein C, a diluent, and a chelating agent.

10. The composition of claim 9 wherein the pharmaceutical composition is a lyophilized formulation.

30

11. The composition of claim 9 wherein the diluent is a reconstitution diluent.

12. The composition of claim 9 wherein the diluent is an intravenous infusion solution.
- 5 13. The composition of claim 9 wherein the chelating agent is present in the diluent.
14. The composition of claim 10 further comprising a bulking agent.
- 10 15. The composition of claim 11 wherein the bulking agent is selected from mannitol, trehalose, raffinose, and sucrose, and mixtures thereof.
16. The composition of claim 12 further comprising a buffer selected from Tris-acetate, sodium citrate and sodium phosphate, or combinations thereof.
- 15 17. The composition of claim 13 further comprising a buffer such that upon reconstitution the formulation has a pH of about 5.5 to about 6.5.
18. The composition of claim 14 further comprising a salt.
- 20 19. The composition of claim 15 wherein the salt is selected from potassium chloride or sodium chloride.
- 25 20. A process for preparing a lyophilized formulation of aPC, which comprises freeze drying a pharmaceutical formulation containing activated protein C and a chelating agent.
21. A process for preparing a lyophilized formulation of aPC, which comprises freeze drying a pharmaceutical formulation containing activated protein C, a bulking agent, and a chelating agent.

- 22 -

22. A process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C with a diluent containing a chelating agent.

5 23. A process of preparing a pharmaceutical solution of aPC, which comprises reconstituting a lyophilized formulation containing activated protein C and a bulking agent with a diluent containing a chelating agent.

10 24. A method of treating a patient in need thereof which comprises administering to the patient the pharmaceutical composition of any one of claims 1 through 19.

25. A use of the pharmaceutical composition of any one of claims 1 through 19 which comprises treating thrombotic disorders.

15199.ST25.txt
SEQUENCE LISTING

<110> Gopalrathnam, Ganapathy
Huang, Lihua
Riggan, Ralph M
Sheliga, Theodore A.

<120> Activated Protein C Formulations

<130> P15199

<140> 60/363364
<141> 2002-03-08

<160> 3

<170> PatentIn version 3.1

<210> 1
<211> 410
<212> PRT
<213> Homo sapiens

<400> 1

His Ser Ser Leu Glu Arg Glu Cys Ile Glu Glu Ile Cys Asp Phe Glu
1 5 10 15

Glu Ala Lys Glu Ile Phe Gln Asn Val Asp Asp Thr Leu Ala Phe Trp
20 25 30

Ser Lys His Val Asp Gly Asp Gln Cys Leu Val Leu Pro Leu Glu His
35 40 45

Pro Cys Ala Ser Leu Cys Cys Gly His Gly Thr Cys Ile Asp Gly Ile
50 55 60

Gly Ser Phe Ser Cys Asp Cys Arg Ser Gly Trp Glu Gly Arg Phe Cys
65 70 75 80

Gln Arg Glu Val Ser Phe Leu Asn Cys Ser Leu Asp Asn Gly Gly Cys
85 90 95

Thr His Tyr Cys Leu Glu Glu Val Gly Trp Arg Arg Cys Ser Cys Ala
100 105 110

Pro Gly Tyr Lys Leu Gly Asp Asp Leu Leu Gln Cys His Pro Ala Val
115 120 125

Lys Phe Pro Cys Gly Arg Pro Trp Lys Arg Met Glu Lys Lys Arg Ser
130 135 140

His Leu Lys Arg Asp Thr Glu Asp Gln Glu Asp Gln Val Asp Pro Arg
145 150 155 160

15199.ST25.txt

Leu Ile Asp Gly Lys Met Thr Arg Arg Gly Asp Ser Pro Trp Gln Val
165 170 175

Val Leu Leu Asp Ser Lys Lys Lys Leu Ala Cys Gly Ala Val Leu Ile
180 185 190

His Pro Ser Trp Val Leu Thr Ala Ala His Cys Met Asp Glu Ser Lys
195 200 205

Lys Leu Leu Val Arg Leu Gly Glu Tyr Asp Leu Arg Arg Trp Glu Lys
210 215 220

Trp Glu Leu Asp Leu Asp Ile Lys Glu Val Phe Val His Pro Asn Tyr
225 230 235 240

Ser Lys Ser Thr Thr Asp Asn Asp Ile Ala Leu Leu His Leu Ala Gln
245 250 255

Pro Ala Thr Leu Ser Gln Thr Ile Val Pro Ile Cys Leu Pro Asp Ser
260 265 270

Gly Leu Ala Glu Arg Glu Leu Asn Gln Ala Gly Gln Glu Thr Leu Val
275 280 285

Thr Gly Trp Gly Tyr His Ser Ser Arg Glu Lys Glu Ala Lys Arg Asn
290 295 300

Arg Thr Phe Val Leu Asn Phe Ile Lys Ile Pro Val Val Pro His Asn
305 310 315 320

Glu Cys Ser Glu Val Met Ser Asn Met Val Ser Glu Asn Met Leu Cys
325 330 335

Ala Gly Ile Leu Gly Asp Arg Gln Asp Ala Cys Glu Gly Asp Ser Gly
340 345 350

Gly Pro Met Val Ala Ser Phe His Gly Thr Trp Phe Leu Val Gly Leu
355 360 365

Val Ser Trp Gly Glu Gly Cys Gly Leu Leu His Asn Tyr Gly Val Tyr
370 375 380

Thr Lys Val Ser Arg Tyr Leu Asp Trp Ile His Gly His Ile Arg Asp
385 390 395 400

Lys Glu Ala Pro Gln Lys Ser Trp Ala Pro
405 410

15199.ST25.txt

<210> 2
<211> 409
<212> PRT
<213> Homo sapiens
<400> 2

Ser Ser Leu Glu Arg Glu Cys Ile Glu Glu Ile Cys Asp Phe Glu Glu
1 5 10 15

Ala Lys Gln Ile Phe Gln Asn Val Asp Asp Thr Leu Ala Phe Trp Ser
20 25 30

Lys His Val Asp Gly Asp Gln Cys Leu Val Leu Pro Leu Glu His Pro
35 40 45

Cys Ala Ser Leu Cys Cys Gly His Gly Thr Cys Ile Asp Gly Ile Gly
50 55 60

Ser Phe Ser Cys Asp Cys Arg Ser Gly Trp Glu Gly Arg Phe Cys Gln
65 70 75 80

Arg Glu Val Ser Phe Leu Asn Cys Ser Leu Asp Asn Gly Gly Cys Thr
85 90 95

His Tyr Cys Leu Glu Glu Val Gly Trp Arg Arg Cys Ser Cys Ala Pro
100 105 110

Gly Tyr Lys Leu Gly Asp Asp Leu Leu Gln Cys His Pro Ala Val Lys
115 120 125

Phe Pro Cys Gly Arg Pro Trp Lys Arg Met Glu Lys Lys Arg Ser His
130 135 140

Leu Lys Arg Asp Thr Glu Asp Gln Glu Asp Gln Val Asp Pro Arg Leu
145 150 155 160

Ile Asp Gly Lys Met Thr Arg Arg Gly Asp Ser Pro Trp Gln Val Val
165 170 175

Leu Leu Asp Ser Lys Lys Leu Ala Cys Gly Ala Val Leu Ile His
180 185 190

Pro Ser Trp Val Leu Thr Ala Ala His Cys Met Asp Glu Ser Lys Lys
195 200 205

Leu Leu Val Arg Leu Gly Glu Tyr Asp Leu Arg Arg Trp Glu Lys Trp
210 215 220

Glu Leu Asp Leu Asp Ile Lys Glu Val Phe Val His Pro Asn Tyr Ser 15199_ST25.txt
225 230 235 240

Lys Ser Thr Thr Asp Asn Asp Ile Ala Leu Leu His Leu Ala Gln Pro 245 250 255

Ala Thr Leu Ser Gln Thr Ile Val Pro Ile Cys Leu Pro Asp Ser Gly 260 265 270

Leu Ala Glu Arg Glu Leu Asn Gln Ala Gly Gln Glu Thr Leu Val Thr 275 280 285

Gly Trp Gly Tyr His Ser Ser Arg Glu Lys Glu Ala Lys Arg Asn Arg 290 295 300

Thr Phe Val Leu Asn Phe Ile Lys Ile Pro Val Val Pro His Asn Glu 305 310 315 320

Cys Ser Glu Val Met Ser Asn Met Val Ser Glu Asn Met Leu Cys Ala 325 330 335

Gly Ile Leu Gly Asp Arg Gln Asp Ala Cys Glu Gly Asp Ser Gly Gly 340 345 350

Pro Met Val Ala Ser Phe His Gly Thr Trp Phe Leu Val Gly Leu Val 355 360 365

Ser Trp Gly Glu Gly Cys Gly Leu Leu His Asn Tyr Gly Val Tyr Thr 370 375 380

Lys Val Ser Arg Tyr Leu Asp Trp Ile His Gly His Ile Arg Asp Lys 385 390 395 400

Glu Ala Pro Gln Lys Ser Trp Ala Pro 405

<210> 3

<211> 419

<212> PRT

<213> Homo sapiens

<400> 3

Ala Asn Ser Phe Leu Glu Glu Leu Arg His Ser Ser Leu Glu Arg Glu 1 5 10 15

Cys Ile Glu Glu Ile Cys Asp Phe Glu Glu Ala Lys Glu Ile Phe Gln 20 25 30

Asn Val Asp Asp Thr Leu Ala Phe Trp Ser Lys His Val Asp Gly Asp 4

35 15199.ST25.txt
40 45Gln Cys Leu Val Leu Pro Leu Glu His Pro Cys Ala Ser Leu Cys Cys
50 55 60Gly His Gly Thr Cys Ile Asp Gly Ile Gly Ser Phe Ser Cys Asp Cys
65 70 75 80Arg Ser Gly Trp Glu Gly Arg Phe Cys Gln Arg Glu Val Ser Phe Leu
85 90 95Asn Cys Ser Leu Asp Asn Gly Gly Cys Thr His Tyr Cys Leu Glu Glu
100 105 110Val Gly Trp Arg Arg Cys Ser Cys Ala Pro Gly Tyr Lys Leu Gly Asp
115 120 125Asp Leu Leu Gln Cys His Pro Ala Val Lys Phe Pro Cys Gly Arg Pro
130 135 140Trp Lys Arg Met Glu Lys Lys Arg Ser His Leu Lys Arg Asp Thr Glu
145 150 155 160Asp Gln Glu Asp Gln Val Asp Pro Arg Leu Ile Asp Gly Lys Met Thr
165 170 175Arg Arg Gly Asp Ser Pro Trp Gln Val Val Leu Leu Asp Ser Lys Lys
180 185 190Lys Leu Ala Cys Gly Ala Val Leu Ile His Pro Ser Trp Val Leu Thr
195 200 205Ala Ala His Cys Met Asp Glu Ser Lys Lys Leu Leu Val Arg Leu Gly
210 215 220Glu Tyr Asp Leu Arg Arg Trp Glu Lys Trp Glu Leu Asp Leu Asp Ile
225 230 235 240Lys Glu Val Phe Val His Pro Asn Tyr Ser Lys Ser Thr Thr Asp Asn
245 250 255Asp Ile Ala Leu Leu His Leu Ala Gln Pro Ala Thr Leu Ser Gln Thr
260 265 270Ile Val Pro Ile Cys Leu Pro Asp Ser Gly Leu Ala Glu Arg Glu Leu
275 280 285

Asn Gln Ala Gly Gln Glu Thr Leu Val Thr Gly Trp Gly Tyr His Ser

290

295

15199.ST25.txt

300

Ser Arg Glu Lys Glu Ala Lys Arg Asn Arg Thr Phe Val Leu Asn Phe
305 310 315 320

Ile Lys Ile Pro Val Val Pro His Asn Glu Cys Ser Glu Val Met Ser
325 330 335

Asn Met Val Ser Glu Asn Met Leu Cys Ala Gly Ile Leu Gly Asp Arg
340 345 350

Gln Asp Ala Cys Glu Gly Asp Ser Gly Gly Pro Met Val Ala Ser Phe
355 360 365

His Gly Thr Trp Phe Leu Val Gly Leu Val Ser Trp Gly Glu Gly Cys
370 375 380

Gly Leu Leu His Asn Tyr Gly Val Tyr Thr Lys Val Ser Arg Tyr Leu
385 390 395 400

Asp Trp Ile His Gly His Ile Arg Asp Lys Glu Ala Pro Gln Lys Ser
405 410 415

Trp Ala Pro

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/05046

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/48; C12N 9/48, 9/96
US CL : 424/94.64; 435/212, 188

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 424/94.64; 435/212, 188

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | US 6,008,199 A (GRINNELL et al.) 28 December 1999. | 1-25 |
| A | US 6,159,408 A (CARLSON et al.) 12 December 2000. | 1-25 |
| A | US 6,162,629 A (BAKER et al.) 19 December 2000. | 1-25 |

| | | | |
|--|--|--|---|
| <input type="checkbox"/> | Further documents are listed in the continuation of Box C. | <input type="checkbox"/> | See patent family annex. |
| • | Special categories of cited documents: | | |
| "A" | document defining the general state of the art which is not considered to be of particular relevance | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" | earlier application or patent published on or after the international filing date | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step |
| "L" | document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone |
| "O" | document referring to an oral disclosure, use, exhibition or other means | "Z" | document of particular relevance; the claimed invention cannot be combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "P" | document published prior to the international filing date but later than the priority date claimed | | document member of the same parent family |
| Date of the actual completion of the international search | | Date of mailing of the international search report | |
| 12 December 2003 (12.12.2003) | | 19 DEC 2003 | |
| Name and mailing address of the ISA/US | | Authorized officer | |
| Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230 | | John P. Weber, Ph.D. | |
| | | Telephone No. (703) 308-0196 | |

INTERNATIONAL SEARCH REPORT

PCT/US03/05046

Continuation of B. FIELDS SEARCHED Item 3:
USPT
search terms: EDTA, activated protein C